1. NSAID Use and Progression of Chronic Kidney Disease
Katherine Gooch, MSc, Bruce F. Culleton, MD, MSc, Braden J. Manns, MD, MSc, Jianguo Zhang, MSc, Helman Alfonso, PhD, Marcello Tonelli, MD, SM, Cy Frank, MD, Scott Klarenbach, MD, MSc, Brenda R. Hemmelgarn, PhD, MD 
The American Journal of Medicine 
Volume 120, Issue 3, Pages 280.e1-280.e7 (March 2007)
DOI: /j.amjmed
Copyright © 2007 Elsevier Inc. Terms and Conditions

2. Figure 1
Formation of study cohort and reasons for exclusion (GFR=glomerular filtration rate).
The American Journal of Medicine  , 280.e1-280.e7DOI: ( /j.amjmed )
Copyright © 2007 Elsevier Inc. Terms and Conditions

3. Figure 2
Distribution of NSAID cumulative dose (defined daily dose) for subjects exposed to at least one NSAID or COX-2 inhibitor.
The American Journal of Medicine  , 280.e1-280.e7DOI: ( /j.amjmed )
Copyright © 2007 Elsevier Inc. Terms and Conditions

4. Figure 3
Relationship between NSAID exposure (defined daily dose) and change in mean glomerular filtration rate (mL/min/1.73m2), adjusting for study mean glomerular filtration rate, age, sex, diabetes and comorbidity (solid continuous line represents predicted point estimates using linear regression, interrupted line represents 95% prediction intervals around these estimates).
The American Journal of Medicine  , 280.e1-280.e7DOI: ( /j.amjmed )
Copyright © 2007 Elsevier Inc. Terms and Conditions